CompletedPhase 3

Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness

United States60 participantsStarted 2013-11-07

Plain-language summary

To compare the efficacy and safety of brimonidine tartrate ophthalmic solution 0.025% with its vehicle for the treatment of ocular redness in a population of adult and geriatric participants with ocular redness.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * At least 18 years of age. * Have a history of redness relief drops use or expressed a desire to use drops for redness relief, within the last 6 months. * Have ocular health within normal limits including a calculated best-corrected visual acuity of 0.3 logarithm of the minimum angle of resolution (logMAR) or better in each eye, as measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Exclusion Criteria: * Any ocular/systemic health problems. * Use of any disallowed medications.

What they're measuring

Ocular Redness as Measured by the Investigator Using the Ora Calibra™ Ocular Hyperemia Scale

Timeframe: 0 (predose), 5, 15, 30, 60, 90, 120, 180, and 240 minutes postdose on Day 1

Trial details

NCT IDNCT01959230

SponsorBausch & Lomb Incorporated

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2013-12-20

Results submitted2019-09-27

View on ClinicalTrials.gov More Hyperemia trials